智通财经APP获悉，Organovo Holdings今日宣布，礼来(LLY.US)（Eli Lilly and ...

FXR314是一款潜在“best-in-class”的口服FXR小分子激动剂。目前，Organovo已获得美国FDA的临床试验许可，正在进行其主打疗法FXR314用于治疗溃疡性结肠炎（UC）的2期试验。公司通过其专有的3D人体组织模型，制定了针对FX ...

Under this transaction, Organovo will receive an upfront payment as well as milestones to be paid as FXR314 achieves key regulatory and commercial milestones. Lilly is acquiring all commercial and ...

全球制药巨头礼来近日宣布以4.5亿美元收购Organovo的FXR项目，这项交易不仅创下2025年开年最大生物技术并购案，更折射出药物研发领域正在经历范式转移。在传统新药研发成功率持续低迷的背景下（2024年Nature数据显示临床阶段药物失败率仍高达85%），Organovo凭借其革命性的3D生物打印技术平台，成功推动FXR314在溃疡性结肠炎等适应症上展现出best-in-class潜力。这场 ...

Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a ...

圣地亚哥 - 专注于3D人体组织模型的生物科技公司Organovo Holdings, Inc. (NASDAQ: ONVO )已达成协议，将其FXR项目（包括主要资产FXR314）出售给制药巨头礼来公司 (NYSE: LLY )。礼来目前市值达到7,940亿美元，股价交易价格高于InvestingPro公平价值。这项交易标志着炎症性肠病 (IBD)治疗领域的重要进展。

Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ ...

Organovo shares are trading higher by 246% Tuesday morning. The company announced that Eli Lilly is set to acquire its FXR ...

Organovo today announced that Eli Lilly and Company (NYSE:LLY) ("Lilly") will acquire Organovo's FXR program, including its ...

The deal with Lilly is a crucial boost for Organovo, which ended last year with just $1.2 million in cash and nearly $350 million in debt. Organovo FXR is a clinical drug program focused on farnesoid ...

A California-based biotech company is finding a tremendous amount of success on Tuesday after the company announced that Eli ...

Eli Lilly (LLY) on Tuesday launched higher doses of Zepbound, or tirzepatide, in single-dose vials and reduced the prices of two smaller doses of the weight-loss drug for self-pay patients. The ...